H.C. Wainwright Remains a Buy on MoonLake Immunotherapeutics (MLTX)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on MoonLake Immunotherapeutics (MLTX) with a $45 price target. This follows BTIG's June 22 report, which also maintained a Buy rating but set a lower $30 target. Selvaraju is recognized as a 5-star analyst in the Healthcare sector.
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on MoonLake Immunotherapeutics today and set a price target of $45.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 23.4% and a 58.68% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Urogen Pharma, and MoonLake Immunotherapeutics.
In a report released on June 22, BTIG also maintained a Buy rating on the stock with a $30.00 price target.